Abstract 4359302: Incidence, Risk Factors, and Outcomes in Triggered Atrial Fibrillation: Insights from the VITAL-AF Trial

J Julian Haimovich (Massachusetts General Hospital, Canton, Massachusetts, United States) S Shinwan Kany (Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, MA (J.S.H., S. Kany, S.A.L., P.T.E., S. Khurshid).) Y Yuchiao Chang (Division of General Internal Medicine, Mass General Brigham, Boston, MA (Y.C., L.H.B., S.J.A., D.E.S.).) L Leila Borowsky (Massachusetts General Hospital, Boston, Massachusetts, United States) D Daniel Singer (Massachusetts General Hospital, Wellesley, Massachusetts, United States) S Steven Atlas (Massachusetts General Hospital, Boston, Massachusetts, United States) S Steven Lubitz (Novartis, Cambridge, Massachusetts, United States) P Patrick Ellinor (The Broad Institute, Cambridge, Massachusetts, United States) S Shaan Khurshid

Abstract

Introduction: Triggered atrial fibrillation (AF), defined as new-onset AF in the setting of a reversible physiological stressor, is common. However, risk factors, outcomes, and management remain poorly understood. Methods: We analyzed data from VITAL-AF, a pragmatic, cluster-randomized AF screening trial (2018-2019) of adults aged 65 and greater across 16 primary care practices affiliated with Massachusetts General Hospital, with 2 years of follow-up and adjudicated incident AF type (triggered vs. primary AF) and clinical outcomes. We compared associations between clinical AF risk factors and incident AF type (i.e, triggered vs non-triggered/primary) using Fine-Gray models. We quantified rates of OAC initiation following AF diagnosis. We then fit Cox proportional hazards models to measure the association between AF type and a composite endpoint of major bleeding, stroke, and all-cause mortality (pre-specified adjudicated VITAL-AF outcomes), with adjustment for CHA 2 DS 2 -VASc (stroke) and ATRIA (bleeding) scores and time-varying OAC exposure. Results: The study included 30,215 patients (59% female, 83% White, mean age 74). Of 998 incident AF events, 290 (29%) were triggered AF. Clinical risk factors including age, hypertension, and heart failure showed similar associations with both primary and triggered AF (Fig. 1). OAC initiation within 90 days of diagnosis was lower for triggered AF than primary AF, notably in medium (63% vs. 79%) and high (54% vs. 74%) CHA 2 DS 2 -VASc risk groups (p<0.05 for both) (Fig. 2). The incidence of the composite endpoint (per 100 person years) was 1.32 (95% CI 1.22-1.43), 8.06 (6.03-10.54), and 7.45 (4.42-11.78), for no AF, primary AF, and triggered AF, respectively (Fig. 3). In adjusted models, both primary (HR 2.23; 95% CI, 1.45-3.43) and triggered AF (HR 2.39; 95% CI, 1.36-4.22) were associated with similarly higher risk of the composite endpoint compared to no AF. Conclusions: Among over 30,000 primary care patients with manually adjudicated events, nearly one-third of incident AF cases were triggered. Despite similar risk factor profiles and similarly higher risk of AF-related adverse outcomes, OAC use appears lower when AF is triggered. Future work is needed to raise awareness of the substantial morbidity and mortality associated with triggered atrial fibrillation and to develop standardized approaches to risk stratification and anticoagulation in this population.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (9)

J

Julian Haimovich

Massachusetts General Hospital, Canton, Massachusetts, United States

S

Shinwan Kany

Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, MA (J.S.H., S. Kany, S.A.L., P.T.E., S. Khurshid).

Y

Yuchiao Chang

Division of General Internal Medicine, Mass General Brigham, Boston, MA (Y.C., L.H.B., S.J.A., D.E.S.).

L

Leila Borowsky

Massachusetts General Hospital, Boston, Massachusetts, United States

D

Daniel Singer

Massachusetts General Hospital, Wellesley, Massachusetts, United States

S

Steven Atlas

Massachusetts General Hospital, Boston, Massachusetts, United States

S

Steven Lubitz

Novartis, Cambridge, Massachusetts, United States

P

Patrick Ellinor

The Broad Institute, Cambridge, Massachusetts, United States

S

Shaan Khurshid